Affymetrix Restructures as Q3 Revenues Drop 14 Percent on Weak Product Sales | GenomeWeb

This story was originally posted on Nov. 3

By Justin Petrone

Facing what some analysts deem "fundamental headwinds" in most of its core businesses, Affymetrix executives this week announced a restructuring of the company and pledged to return the beleaguered array vendor to growth in 2012.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.